Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.

This study is testing a new approach to bone marrow transplantation (also called stem cell transplantation) for people with blood cancers. The new approach uses a modified form of G-CSF (a drug that stimulates the body to release stem cells into the blood) called pegylated G-CSF to collect stem cells from a matching sibling donor. The transplant is then used to treat the patient's blood cancer. Researchers want to see if this method is safe and effective. You may be eligible if: - You are 70 years old or younger - You have been diagnosed with a blood cancer (such as leukaemia or lymphoma) - You have a brother or sister who is a matching donor (HLA-identical sibling) - Your general health status is good enough for transplant (ECOG performance status 0–2) - Your donor sibling is fit to donate stem cells You may NOT be eligible if: - There are no specific exclusion criteria listed for this study Talk to your doctor about whether this trial might be right for you.